Scholarlink

Background <p>Advanced colorectal cancer (CRC) is an aggressive subtype with a poor prognosis, highlighting the need for effective biomarkers. Karyopherin alpha 2 (KPNA2), a nuclear transport protein, facilitates the expression of oncogenic transcription factors (e.g. c-Myc). However, the clinical and functional implications of KPNA2 expression in pathological T4 (pT4) CRC in relation to the status of p53, a tumour suppressor, and c-Myc regulation remain unclear.</p> Methods <p>KPNA2 and p53 expression in 78 surgically resected pT4 CRC samples was assessed using immunohistochemistry. Functional analyses were conducted using short hairpin RNA-mediated KPNA2 knockdown in p53-mutant, wild-type p53 and p53-null CRC cell lines.</p> Results <p>High KPNA2 expression significantly associated with aggressive tumour characteristics and poor prognosis, particularly in the wild-type p53 patient subgroup. Clinically, elevated KPNA2 levels correlated with increased distant metastasis rates and reduced disease-free survival, especially in patients with wild-type p53 receiving adjuvant chemotherapy. KPNA2 suppression reduced cell proliferation, inhibited xenograft tumour growth and selectively enhanced 5-FU and oxaliplatin sensitivity in wild-type p53 CRC cells. KPNA2 knockdown impaired nuclear c-Myc transport and induced p53-dependent p21 expression; however, these effects were not observed in p53-mutant or p53-null CRC.</p> Conclusions <p>KPNA2 expression may serve as an important prognostic biomarker and therapeutic target in patients with locally advanced wild-type p53 CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

High KPNA2 expression predicts poor prognosis in pathological T4 colorectal cancer by importing c-Myc into the nucleus to suppress p53-dependent p21 expression

  • 期刊论文

  • 发表日期：

    2026年7月17日

查看全文
  • Gendensuren Dorjkhorloo,
  • Bilguun Erkhem-Ochir,
  • Takuya Shiraishi,
  • Haruka Okami,
  • Arisa Yamaguchi,
  • Ikuma Shioi,
  • Nobuhiro Hosoi,
  • Chika Komine,
  • Nobuhiro Nakazawa,
  • Yuta Shibasaki,
  • Takuhisa Okada,
  • Katsuya Osone,
  • Akihiko Sano,
  • Makoto Sakai,
  • Atsushi Shibata,
  • Takehiko Yokobori,
  • Ken Shirabe,
  • Hiroshi Saeki

摘要

Background

Advanced colorectal cancer (CRC) is an aggressive subtype with a poor prognosis, highlighting the need for effective biomarkers. Karyopherin alpha 2 (KPNA2), a nuclear transport protein, facilitates the expression of oncogenic transcription factors (e.g. c-Myc). However, the clinical and functional implications of KPNA2 expression in pathological T4 (pT4) CRC in relation to the status of p53, a tumour suppressor, and c-Myc regulation remain unclear.

Methods

KPNA2 and p53 expression in 78 surgically resected pT4 CRC samples was assessed using immunohistochemistry. Functional analyses were conducted using short hairpin RNA-mediated KPNA2 knockdown in p53-mutant, wild-type p53 and p53-null CRC cell lines.

Results

High KPNA2 expression significantly associated with aggressive tumour characteristics and poor prognosis, particularly in the wild-type p53 patient subgroup. Clinically, elevated KPNA2 levels correlated with increased distant metastasis rates and reduced disease-free survival, especially in patients with wild-type p53 receiving adjuvant chemotherapy. KPNA2 suppression reduced cell proliferation, inhibited xenograft tumour growth and selectively enhanced 5-FU and oxaliplatin sensitivity in wild-type p53 CRC cells. KPNA2 knockdown impaired nuclear c-Myc transport and induced p53-dependent p21 expression; however, these effects were not observed in p53-mutant or p53-null CRC.

Conclusions

KPNA2 expression may serve as an important prognostic biomarker and therapeutic target in patients with locally advanced wild-type p53 CRC.